查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2008761

循環性腫瘤細胞市場報告：按技術、應用、產品、檢體、最終用戶和地區分類（2026-2034 年）

Circulating Tumor Cells Market Report by Technology, Application, Product, Specimen, End User, and Region 2026-2034
出版日期: | 出版商: IMARC | 英文 138 Pages | 商品交期: 2-3個工作天內

價格

全球循環性腫瘤細胞(CTC) 市場規模在 2025 年達到 140 億美元。 IMARC 集團預測，到 2034 年，該市場規模將達到 280 億美元，2026 年至 2034 年的複合年成長率 (CAGR) 為 7.80%。北美市場佔據主導地位，這主要得益於技術進步和研發投入的增加。由於微創性，醫院正在採用包括 CTC 分析在內的液態生物檢體技術。此外，生活方式的改變導致遺傳性疾病發生率上升，也推動了市場佔有率的擴大。

循環性腫瘤細胞（CTC）市場趨勢：

全球癌症發生率上升

全球癌症發生率的上升正在推動市場擴張。隨著癌症患者數量的增加，對更有效率、更微創的診斷解決方案的需求也隨之增加。根據印度醫學研究理事會 (ICMR) 預測，到 2025 年，癌症患者數量將比 2020 年增加 12.8%。每年新增病例數以百萬計，迫使醫療系統實施創新策略，以進行早期檢測、後續觀察和治療方案製定。循環性腫瘤細胞(CTC) 正成為腫瘤科醫師的首選，因為它們無需重複進行侵入性切片檢查即可提供有關腫瘤進展和轉移的關鍵資訊。乳癌、攝護腺癌和肺癌等進行性癌症發生率的不斷上升進一步凸顯了基於 CTC 的診斷方法的必要性。隨著患者和臨床醫生對即時後續觀察的需求日益成長，CTC 的重要性也顯著提升。

精準醫療與個人化醫療的發展

精準醫療和個人化治療的進步正使癌症治療更具針對性和有效性。根據IMARC Group預測，全球精準醫療市場規模預計在2024年達到821億美元。循環腫瘤細胞（CTC）能夠即時分析腫瘤生物學特徵，幫助臨床醫師根據患者的個別狀況最佳化治療方案，而非採用千篇一律的治療模式。這推動了治療方法朝向最大限度提高療效、同時最大限度減少副作用的方向發展。透過識別特定的基因突變、抗藥性模式和腫瘤進展，CTC分析提高了個人化治療的成功率。製藥公司也在臨床試驗中利用CTC來評估治療反應，並加速藥物研發進程。隨著精準醫療在全球蓬勃發展，對基於CTC的診斷和監測的需求也在不斷成長，成為下一代癌症管理策略的重要組成部分。

人們對液態生物檢體的認知不斷提高

隨著人們對液態生物檢體的認知不斷提高，市場前景一片光明，患者和醫療專業人員都認知到它比傳統組織切片檢查更具優勢。醫院正在採用液態生物檢體，包括循環腫瘤細胞（CTC）分析，因為這些技術具有微創、快速出結果以及能夠即時監測腫瘤變化等優點。 2025年7月，位於古爾岡的福蒂斯紀念研究所（FMRI）與Aguilas Diagnostics公司合作，部署了其第二套Genexus系統。 Genexus平台能夠快速完成基於NGS（次世代定序）的檢測，包括24小時內液態生物檢體、72小時內完成骨髓NGS檢測以及5天內微量殘存疾病（MRD）檢測。與手術切片檢查不同，液態生物檢體可以更頻繁地進行，從而能夠持續評估治療效果並及早發現抗藥性。醫療機構所進行的宣傳宣傳活動，以及科學技術的進步，也正在推動液體切片在腫瘤學領域的應用。

循環性腫瘤細胞（CTC）市場的主要成長要素：

CTC分離與檢測技術的進展

循環腫瘤細胞 (CTC) 分離和檢測技術的進步正在提高癌症診斷的準確性、靈敏度和效率。從血液樣本中分離稀有 CTC 的傳統難題正被基於微流體、免疫磁分離和奈米技術的創新平台所克服。這些先進技術改進了 CTC 的捕獲和分析，從而能夠可靠地揭示腫瘤的生物學特徵和進展。檢測能力的提升使得監測微量殘存疾病和識別抗藥性成為可能，並支持制定個人化治療方案。隨著技術的進步，成本逐漸降低，使得這些解決方案更容易被醫院和檢查室採用。臨床可靠性的提高和更廣泛的應用正在顯著推動 CTC 市場的成長和應用範圍的擴大。

增加基於循環腫瘤細胞（CTC）的診斷試劑盒的監管核准

基於循環腫瘤細胞（CTC）的診斷試劑盒獲得越來越多的監管核准，這透過提升其可靠性、可及性和臨床應用，對市場產生了積極影響。監管機構正在核准新的CTC分離和檢測系統，以確保其安全性、可靠性和臨床效用。這些核准不僅驗證了這些技術的有效性，也鼓勵醫療專業人員將其整合到標準的癌症診療流程中。此外，監管核准還有助於企業以合規產品進入新市場，並拓展其全球業務。已通過核准盒的普及也加速了生技公司、醫院和研究機構之間的合作。隨著越來越多的診斷產品獲得官方批准，CTC市場因其在癌症早期檢測、預後預測和患者後續觀察的作用而日益受到認可。

政府和私人部門加大對癌症診斷領域的投入

政府和私人機構對癌症診斷領域的資金籌措不斷增加，正在加速研究、創新和先進技術的應用。世界各國政府機構都在增加醫療保健預算和癌症研究津貼，以應對日益沉重的癌症負擔，而私人投資者則在資助專注於循環腫瘤細胞（CTC）應用的生物技術Start-Ups。這些資金支持推動了分離技術、分子檢測和液態生物檢體平台的發展，從而提高了診斷的準確性和成本效益。資金也支持進行大規模臨床試驗，以檢驗CTC在監測和治療方法選擇方面的臨床應用價值。此外，資金籌措機會的增加也促進了研究機構、醫院和私人企業之間的合作。隨著投資的持續成長，CTC市場正經歷更快速的成長，使更完善的解決方案能夠更快地惠及病患。

目錄

第1章：序言

第2章：調查方法

  • 調查目的
  • 相關利益者
  • 數據來源
    • 主要訊息
    • 二手資訊
  • 市場估值
    • 自下而上的方法
    • 自上而下的方法
  • 預測方法

第3章執行摘要

第4章：引言

第5章：全球循環性腫瘤細胞市場

  • 市場概覽
  • 市場表現
  • 新冠疫情的影響
  • 市場預測

第6章 市場區隔：依技術分類

  • CTC檢測與濃縮方法
  • CTC直接檢測方法
  • CTC分析

第7章 市場區隔：依應用領域分類

  • 臨床/液態生物檢體
    • 主要部分
      • 風險評估
      • 篩檢和監測
  • 研究
    • 主要部分
      • 癌症幹細胞和腫瘤發生的研究
      • 藥物和治療方法研發

第8章 市場區隔：依產品分類

  • 試劑盒和試劑
  • 採血管
  • 設備或系統

第9章 市場區隔：依檢體

  • 血
  • 骨髓
  • 其他體液

第10章 市場區隔：依最終用戶分類

  • 醫院和診所
  • 研究和學術機構
  • 診斷中心

第11章 市場區隔：按地區分類

  • 北美洲
    • 美國
    • 加拿大
  • 亞太地區
    • 中國
    • 日本
    • 印度
    • 韓國
    • 澳洲
    • 印尼
    • 其他
  • 歐洲
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙
    • 俄羅斯
    • 其他
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 其他
  • 中東和非洲

第12章 SWOT 分析

第13章：價值鏈分析

第14章：波特五力分析

第15章：價格分析

第16章 競爭格局

  • 市場結構
  • 主要企業
  • 主要企業簡介
    • BioFluidica
    • Bio-Techne
    • Cell Microsystems
    • Creatv MicroTech Inc.
    • CytoLumina
    • Ikonisys Inc.
    • Menarini Silicon Biosystems Inc.
    • Miltenyi Biotec
    • Precision Medicine Group, LLC
    • Qiagen NV
    • Rarecells, Inc.
    • Stemcell Technologies
    • Thermo Fisher Scientific Inc.
Product Code: SR112026A6316

The global circulating tumor cells (CTC) market size reached USD 14.0 Billion in 2025. Looking forward, IMARC Group expects the market to reach USD 28.0 Billion by 2034, exhibiting a growth rate (CAGR) of 7.80% during 2026-2034. North America dominates the market, driven by advancements in technologies and increasing investments in research and development (R&D) activities. Hospitals are implementing liquid biopsy techniques, such as CTC analysis, because of their low invasiveness. The high occurrence of genetic disorders, due to lifestyle alterations, is fueling the market share.

CIRCULATING TUMOR CELLS (CTC) MARKET ANALYSIS:

  • Major Market Drivers: The inflating need for real-time monitoring and early identification of breast, lung, digestive tract, and prostate cancer is bolstering the market.
  • Key Market Trends: The widespread adoption of minimally invasive (MI) diagnostic procedures is acting as a significant growth-inducing factor.
  • Competitive Landscape: Some of the prominent companies in the market include BioFluidica, Bio-Techne, Cell Microsystems, Creatv MicroTech Inc., CytoLumina, Ikonisys Inc., Menarini Silicon Biosystems Inc., Miltenyi Biotec, Precision Medicine Group, LLC, Qiagen N.V., Rarecells, Inc., Stemcell Technologies, and Thermo Fisher Scientific Inc., among many others.
  • Geographical Trends: The rising investments in medical research to develop cell culture models for disease modeling, genome editing, drug screening, and tumor immunity are contributing to the market in North America.
  • Challenges and Opportunities: The high complexity of analysis technologies is hindering the market. However, the development of more affordable, simplified, and high-throughput methods for CTC isolation is expected to fuel the market over the forecasted period.

CIRCULATING TUMOR CELLS (CTC) MARKET TRENDS:

Rising global cancer prevalence

Increasing global cancer prevalence is fueling the market expansion, as the growing number of cancer cases is demanding more efficient and less invasive diagnostic solutions. As per the Indian Council of Medical Research, a projected 12.8% rise in cancer cases is anticipated by 2025 in comparison to 2020. With millions of new cases documented each year, healthcare systems are facing pressure to implement inventive strategies for early detection, monitoring, and treatment direction. CTCs offer important information on tumor development and metastasis without needing repeated invasive biopsies, thus becoming a favored choice for oncologists. The increasing prevalence of aggressive cancers like breast, prostate, and lung cancer is further driving the need for diagnostics based on CTCs. With patients and clinicians pursuing real-time tracking, the importance of CTCs is growing significantly.

Growth of precision medicine and personalized therapies

The growth of precision medicine and personalized therapies is making cancer care more targeted and effective. As per the IMARC Group, the global precision medicine market size reached USD 82.1 Billion in 2024. CTCs enable real-time analysis of tumor biology, helping clinicians tailor treatments based on individual patient profiles rather than generic approaches. This supports the growing shift towards therapies that maximize efficacy while minimizing side effects. By identifying specific genetic mutations, drug resistance patterns, and tumor progression, CTC analysis enhances the success rate of personalized therapies. Pharmaceutical companies are also using CTCs in clinical trials to evaluate treatment responses, accelerating drug development pipelines. As precision medicine is gaining momentum worldwide, the demand for CTC-based diagnostics and monitoring is expanding, making them an integral component of next-generation cancer management strategies.

Increasing awareness about liquid biopsy

Rising awareness about liquid biopsy is offering a favorable market outlook, as both patients and healthcare providers are recognizing its benefits over traditional tissue biopsies. Hospitals are adopting liquid biopsy methods, including CTC analysis, due to their minimally invasive nature, faster results, and ability to monitor tumor changes in real-time. In July 2025, Fortis Memorial Research Institute (FMRI) in Gurugram, collaborating with Agilus Diagnostics, launched its second Genexus system. The Genexus platform provided NGS-based tests with a quicker turnaround, such as Liquid Biopsy in 24 hours, Myeloid NGS in 72 hours, and minimal residual disease (MRD) testing in five days. Unlike surgical biopsies, liquid biopsies can be performed more frequently, allowing continuous assessment of treatment effectiveness and early detection of resistance. Awareness campaigns by healthcare organizations, combined with scientific advancements, are also encouraging adoption in oncology departments.

KEY GROWTH DRIVERS OF CIRCULATING TUMOR CELLS (CTC) MARKET:

Advancements in CTC isolation and detection technologies

Advancements in CTC isolation and detection technologies are improving accuracy, sensitivity, and efficiency in cancer diagnostics. Traditional challenges in isolating rare CTCs from blood samples are being addressed through innovations in microfluidics, immunomagnetic separation, and nanotechnology-based platforms. These advanced methods enable better capture and analysis of CTCs, providing reliable insights into tumor biology and progression. Enhanced detection capabilities also allow monitoring minimal residual disease and identifying drug resistance, which supports personalized treatment planning. As technology is evolving, costs are gradually decreasing, making these solutions more accessible to hospitals and laboratories. With improved clinical reliability and wider adoption, technological progress is significantly fueling the growth and application scope of the CTC market.

Rising regulatory approvals for CTC-based diagnostic kits

Increasing regulatory approvals for CTC-based diagnostic kits are positively influencing the market by enhancing trust, accessibility, and clinical adoption. Regulatory bodies are granting approvals for new CTC isolation and detection systems, ensuring their safety, reliability, and clinical utility. These approvals not only validate the effectiveness of such technologies but also encourage healthcare providers to integrate them into standard cancer care practices. Moreover, regulatory clearances help companies expand globally, reaching new markets with compliant products. The availability of approved kits is also accelerating collaborations between biotech firms, hospitals, and research institutions. As more diagnostic products are gaining official authorization, the CTC market is witnessing stronger adoption, its function in the early identification, outlook, and observation of cancer patients.

Increasing government and private funding in cancer diagnostics

Rising government and private funding in cancer diagnostics is accelerating research, innovations, and adoption of advanced technologies. Government agencies worldwide are increasing healthcare budgets and cancer research grants to combat the growing cancer burden, while private investors are funding biotech startups focused on CTC applications. This financial support is fostering advancements in isolation techniques, molecular assays, and liquid biopsy platforms, making diagnostics more accurate and affordable. Funding also facilitates large-scale clinical trials, validating the clinical employment of CTCs in monitoring and therapy selection. Moreover, collaborations between research institutions, hospitals, and private firms are expanding due to increased capital availability. As investments continue to rise, the CTC market is experiencing faster growth, with improved solutions reaching patients more rapidly.

GLOBAL CIRCULATING TUMOR CELLS (CTC) INDUSTRY SEGMENTATION:

Breakup by Technology:

  • CTC Detection and Enrichment Method
  • CTC Direct Detection Methods
  • CTC Analysis

CTC detection and enrichment method dominate the market

CTC detection and enrichment method enhances the specificity, sensitivity, and efficiency of CTC isolation from blood samples. One of the notable launches is the CellSearch system, the first FDA-approved technology for CTC detection in metastatic breast cancer.

Breakup by Application:

  • Clinical/Liquid Biopsy
    • Risk Assessment
    • Screening and Monitoring
  • Research
    • Cancer Stem Cell and Tumorigenesis Research
    • Drug/Therapy Development

Research currently holds most of the total circulating tumor cells (CTC) market share

The introduction of cutting-edge methodologies and technologies aimed at enhancing CTC characterization, detection, and clinical application is augmenting the segment's growth.

Breakup by Product:

  • Kits and Reagents
  • Blood Collection Tubes
  • Devices and Systems

Devices and systems hold the majority of the global circulating tumor cells (CTC) market demand

The inflating need for cancer detection and monitoring is acting as a significant growth-inducing factor. The ClearCell FX system launched a label-free, microfluidic approach that improved cell purity and viability.

Breakup by Specimen:

  • Blood
  • Bone Marrow
  • Other Body Fluids

Blood dominates the circulating tumor cells (CTC) market outlook

The analysis of circulating tumor cells (CTCs) in the blood stimulates the capabilities and applications of this technology in oncology. For example, the ClearCell FX system gained traction, as it is a novel label-free, microfluidic technique, which enhanced the isolation process.

Breakup by End User:

  • Hospital and Clinics
  • Research and Academic Institutes
  • Diagnostic Centres

Hospitals and clinics need enhanced patient care through more personalized and timely interventions. Research and academic institutes leverage CTC technologies to understand tumor biology, advance cancer research, and develop new therapeutic strategies. Diagnostic centers further offer early cancer detection and monitoring of treatment efficacy. As per the circulating tumor cells (CTC) market forecast report, this is acting as a significant growth-inducing factor.

Breakup by Region:

  • North America
    • United States
    • Canada
  • Asia-Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Indonesia
    • Others
  • Europe
    • Germany
    • France
    • United Kingdom
    • Italy
    • Spain
    • Russia
    • Others
  • Latin America
    • Brazil
    • Mexico
    • Others
  • Middle East and Africa

North America exhibits a clear dominance in the market

The circulating tumor cells (CTC) market research report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America accounted for the largest market share.

The increasing prevalence of cancer is augmenting the market. Moreover, the escalating demand for cancer immunotherapy in the United States will continue to fuel the market in the coming years. According to the IMARC, the United States cancer immunotherapy market size is expected to exhibit a growth rate (CAGR) of approximately 10.90% during 2024-2032.

COMPETITIVE LANDSCAPE:

The market research report has provided a comprehensive analysis of the competitive landscape. Detailed profiles of all major market companies have also been provided. Some of the key players in the market include:

  • BioFluidica
  • Bio-Techne
  • Cell Microsystems
  • Creatv MicroTech Inc.
  • CytoLumina
  • Ikonisys Inc.
  • Menarini Silicon Biosystems Inc.
  • Miltenyi Biotec
  • Precision Medicine Group, LLC
  • Qiagen N.V.
  • Rarecells, Inc.
  • Stemcell Technologies
  • Thermo Fisher Scientific Inc.

()

KEY QUESTIONS ANSWERED IN THIS REPORT

1. What was the size of the global Circulating Tumor Cells (CTC) market in 2025?

2. What is the expected growth rate of the global Circulating Tumor Cells (CTC) market during 2026-2034?

3. What are the key factors driving the global Circulating Tumor Cells (CTC) market?

4. What has been the impact of COVID-19 on the global Circulating Tumor Cells (CTC) market?

5. What is the breakup of the global circulating tumor cells (CTC) market based on technology?

6. What is the breakup of the global Circulating Tumor Cells (CTC) market based on the application?

7. What is the breakup of the global Circulating Tumor Cells (CTC) market based on the product?

8. What is the breakup of the global Circulating Tumor Cells (CTC) market based on the specimen?

9. What are the key regions in the global Circulating Tumor Cells (CTC) market?

10. Who are the key players/companies in the global Circulating Tumor Cells (CTC) market?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Circulating Tumor Cells (CTC) Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Technology

  • 6.1 CTC Detection and Enrichment Method
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 CTC Direct Detection Methods
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast
  • 6.3 CTC Analysis
    • 6.3.1 Market Trends
    • 6.3.2 Market Forecast

7 Market Breakup by Application

  • 7.1 Clinical/Liquid Biopsy
    • 7.1.1 Market Trends
    • 7.1.2 Key Segments
      • 7.1.2.1 Risk Assessment
      • 7.1.2.2 Screening and Monitoring
    • 7.1.3 Market Forecast
  • 7.2 Research
    • 7.2.1 Market Trends
    • 7.2.2 Key Segments
      • 7.2.2.1 Cancer Stem Cell and Tumorigenesis Research
      • 7.2.2.2 Drug/Therapy Development
    • 7.2.3 Market Forecast

8 Market Breakup by Product

  • 8.1 Kits and Reagents
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 Blood Collection Tubes
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast
  • 8.3 Devices or Systems
    • 8.3.1 Market Trends
    • 8.3.2 Market Forecast

9 Market Breakup by Specimen

  • 9.1 Blood
    • 9.1.1 Market Trends
    • 9.1.2 Market Forecast
  • 9.2 Bone Marrow
    • 9.2.1 Market Trends
    • 9.2.2 Market Forecast
  • 9.3 Other Body Fluids
    • 9.3.1 Market Trends
    • 9.3.2 Market Forecast

10 Market Breakup by End User

  • 10.1 Hospital and Clinics
    • 10.1.1 Market Trends
    • 10.1.2 Market Forecast
  • 10.2 Research and Academic Institutes
    • 10.2.1 Market Trends
    • 10.2.2 Market Forecast
  • 10.3 Diagnostic Centres
    • 10.3.1 Market Trends
    • 10.3.2 Market Forecast

11 Market Breakup by Region

  • 11.1 North America
    • 11.1.1 United States
      • 11.1.1.1 Market Trends
      • 11.1.1.2 Market Forecast
    • 11.1.2 Canada
      • 11.1.2.1 Market Trends
      • 11.1.2.2 Market Forecast
  • 11.2 Asia-Pacific
    • 11.2.1 China
      • 11.2.1.1 Market Trends
      • 11.2.1.2 Market Forecast
    • 11.2.2 Japan
      • 11.2.2.1 Market Trends
      • 11.2.2.2 Market Forecast
    • 11.2.3 India
      • 11.2.3.1 Market Trends
      • 11.2.3.2 Market Forecast
    • 11.2.4 South Korea
      • 11.2.4.1 Market Trends
      • 11.2.4.2 Market Forecast
    • 11.2.5 Australia
      • 11.2.5.1 Market Trends
      • 11.2.5.2 Market Forecast
    • 11.2.6 Indonesia
      • 11.2.6.1 Market Trends
      • 11.2.6.2 Market Forecast
    • 11.2.7 Others
      • 11.2.7.1 Market Trends
      • 11.2.7.2 Market Forecast
  • 11.3 Europe
    • 11.3.1 Germany
      • 11.3.1.1 Market Trends
      • 11.3.1.2 Market Forecast
    • 11.3.2 France
      • 11.3.2.1 Market Trends
      • 11.3.2.2 Market Forecast
    • 11.3.3 United Kingdom
      • 11.3.3.1 Market Trends
      • 11.3.3.2 Market Forecast
    • 11.3.4 Italy
      • 11.3.4.1 Market Trends
      • 11.3.4.2 Market Forecast
    • 11.3.5 Spain
      • 11.3.5.1 Market Trends
      • 11.3.5.2 Market Forecast
    • 11.3.6 Russia
      • 11.3.6.1 Market Trends
      • 11.3.6.2 Market Forecast
    • 11.3.7 Others
      • 11.3.7.1 Market Trends
      • 11.3.7.2 Market Forecast
  • 11.4 Latin America
    • 11.4.1 Brazil
      • 11.4.1.1 Market Trends
      • 11.4.1.2 Market Forecast
    • 11.4.2 Mexico
      • 11.4.2.1 Market Trends
      • 11.4.2.2 Market Forecast
    • 11.4.3 Others
      • 11.4.3.1 Market Trends
      • 11.4.3.2 Market Forecast
  • 11.5 Middle East and Africa
    • 11.5.1 Market Trends
    • 11.5.2 Market Breakup by Country
    • 11.5.3 Market Forecast

12 SWOT Analysis

  • 12.1 Overview
  • 12.2 Strengths
  • 12.3 Weaknesses
  • 12.4 Opportunities
  • 12.5 Threats

13 Value Chain Analysis

14 Porters Five Forces Analysis

  • 14.1 Overview
  • 14.2 Bargaining Power of Buyers
  • 14.3 Bargaining Power of Suppliers
  • 14.4 Degree of Competition
  • 14.5 Threat of New Entrants
  • 14.6 Threat of Substitutes

15 Price Analysis

16 Competitive Landscape

  • 16.1 Market Structure
  • 16.2 Key Players
  • 16.3 Profiles of Key Players
    • 16.3.1 BioFluidica
      • 16.3.1.1 Company Overview
      • 16.3.1.2 Product Portfolio
    • 16.3.2 Bio-Techne
      • 16.3.2.1 Company Overview
      • 16.3.2.2 Product Portfolio
    • 16.3.3 Cell Microsystems
      • 16.3.3.1 Company Overview
      • 16.3.3.2 Product Portfolio
    • 16.3.4 Creatv MicroTech Inc.
      • 16.3.4.1 Company Overview
      • 16.3.4.2 Product Portfolio
    • 16.3.5 CytoLumina
      • 16.3.5.1 Company Overview
      • 16.3.5.2 Product Portfolio
    • 16.3.6 Ikonisys Inc.
      • 16.3.6.1 Company Overview
      • 16.3.6.2 Product Portfolio
    • 16.3.7 Menarini Silicon Biosystems Inc.
      • 16.3.7.1 Company Overview
      • 16.3.7.2 Product Portfolio
    • 16.3.8 Miltenyi Biotec
      • 16.3.8.1 Company Overview
      • 16.3.8.2 Product Portfolio
    • 16.3.9 Precision Medicine Group, LLC
      • 16.3.9.1 Company Overview
      • 16.3.9.2 Product Portfolio
    • 16.3.10 Qiagen N.V.
      • 16.3.10.1 Company Overview
      • 16.3.10.2 Product Portfolio
    • 16.3.11 Rarecells, Inc.
      • 16.3.11.1 Company Overview
      • 16.3.11.2 Product Portfolio
    • 16.3.12 Stemcell Technologies
      • 16.3.12.1 Company Overview
      • 16.3.12.2 Product Portfolio
    • 16.3.13 Thermo Fisher Scientific Inc.
      • 16.3.13.1 Company Overview
      • 16.3.13.2 Product Portfolio

List of Figures

  • Figure 1: Global: Circulating Tumor Cells Market: Major Drivers and Challenges
  • Figure 2: Global: Circulating Tumor Cells Market: Sales Value (in Billion USD), 2020-2025
  • Figure 3: Global: Circulating Tumor Cells Market Forecast: Sales Value (in Billion USD), 2026-2034
  • Figure 4: Global: Circulating Tumor Cells Market: Breakup by Technology (in %), 2025
  • Figure 5: Global: Circulating Tumor Cells Market: Breakup by Application (in %), 2025
  • Figure 6: Global: Circulating Tumor Cells Market: Breakup by Product (in %), 2025
  • Figure 7: Global: Circulating Tumor Cells Market: Breakup by Specimen (in %), 2025
  • Figure 8: Global: Circulating Tumor Cells Market: Breakup by End User (in %), 2025
  • Figure 9: Global: Circulating Tumor Cells Market: Breakup by Region (in %), 2025
  • Figure 10: Global: Circulating Tumor Cells (CTC Detection and Enrichment Method) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 11: Global: Circulating Tumor Cells (CTC Detection and Enrichment Method) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 12: Global: Circulating Tumor Cells (CTC Direct Detection Methods) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 13: Global: Circulating Tumor Cells (CTC Direct Detection Methods) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 14: Global: Circulating Tumor Cells (CTC Analysis) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 15: Global: Circulating Tumor Cells (CTC Analysis) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 16: Global: Circulating Tumor Cells (Clinical/Liquid Biopsy) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 17: Global: Circulating Tumor Cells (Clinical/Liquid Biopsy) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 18: Global: Circulating Tumor Cells (Research) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 19: Global: Circulating Tumor Cells (Research) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 20: Global: Circulating Tumor Cells (Kits and Reagents) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 21: Global: Circulating Tumor Cells (Kits and Reagents) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 22: Global: Circulating Tumor Cells (Blood Collection Tubes) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 23: Global: Circulating Tumor Cells (Blood Collection Tubes) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 24: Global: Circulating Tumor Cells (Devices or Systems) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 25: Global: Circulating Tumor Cells (Devices or Systems) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 26: Global: Circulating Tumor Cells (Blood) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 27: Global: Circulating Tumor Cells (Blood) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 28: Global: Circulating Tumor Cells (Bone Marrow) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 29: Global: Circulating Tumor Cells (Bone Marrow) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 30: Global: Circulating Tumor Cells (Other Body Fluids) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 31: Global: Circulating Tumor Cells (Other Body Fluids) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 32: Global: Circulating Tumor Cells (Hospital and Clinics) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 33: Global: Circulating Tumor Cells (Hospital and Clinics) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 34: Global: Circulating Tumor Cells (Research and Academic Institutes) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 35: Global: Circulating Tumor Cells (Research and Academic Institutes) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 36: Global: Circulating Tumor Cells (Diagnostic Centres) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 37: Global: Circulating Tumor Cells (Diagnostic Centres) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 38: North America: Circulating Tumor Cells Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 39: North America: Circulating Tumor Cells Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 40: United States: Circulating Tumor Cells Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 41: United States: Circulating Tumor Cells Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 42: Canada: Circulating Tumor Cells Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 43: Canada: Circulating Tumor Cells Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 44: Asia-Pacific: Circulating Tumor Cells Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 45: Asia-Pacific: Circulating Tumor Cells Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 46: China: Circulating Tumor Cells Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 47: China: Circulating Tumor Cells Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 48: Japan: Circulating Tumor Cells Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 49: Japan: Circulating Tumor Cells Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 50: India: Circulating Tumor Cells Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 51: India: Circulating Tumor Cells Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 52: South Korea: Circulating Tumor Cells Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 53: South Korea: Circulating Tumor Cells Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 54: Australia: Circulating Tumor Cells Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 55: Australia: Circulating Tumor Cells Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 56: Indonesia: Circulating Tumor Cells Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 57: Indonesia: Circulating Tumor Cells Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 58: Others: Circulating Tumor Cells Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 59: Others: Circulating Tumor Cells Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 60: Europe: Circulating Tumor Cells Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 61: Europe: Circulating Tumor Cells Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 62: Germany: Circulating Tumor Cells Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 63: Germany: Circulating Tumor Cells Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 64: France: Circulating Tumor Cells Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 65: France: Circulating Tumor Cells Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 66: United Kingdom: Circulating Tumor Cells Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 67: United Kingdom: Circulating Tumor Cells Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 68: Italy: Circulating Tumor Cells Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 69: Italy: Circulating Tumor Cells Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 70: Spain: Circulating Tumor Cells Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 71: Spain: Circulating Tumor Cells Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 72: Russia: Circulating Tumor Cells Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 73: Russia: Circulating Tumor Cells Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 74: Others: Circulating Tumor Cells Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 75: Others: Circulating Tumor Cells Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 76: Latin America: Circulating Tumor Cells Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 77: Latin America: Circulating Tumor Cells Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 78: Brazil: Circulating Tumor Cells Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 79: Brazil: Circulating Tumor Cells Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 80: Mexico: Circulating Tumor Cells Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 81: Mexico: Circulating Tumor Cells Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 82: Others: Circulating Tumor Cells Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 83: Others: Circulating Tumor Cells Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 84: Middle East and Africa: Circulating Tumor Cells Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 85: Middle East and Africa: Circulating Tumor Cells Market: Breakup by Country (in %), 2025
  • Figure 86: Middle East and Africa: Circulating Tumor Cells Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 87: Global: Circulating Tumor Cells Industry: SWOT Analysis
  • Figure 88: Global: Circulating Tumor Cells Industry: Value Chain Analysis
  • Figure 89: Global: Circulating Tumor Cells Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Circulating Tumor Cells Market: Key Industry Highlights, 2025 and 2034
  • Table 2: Global: Circulating Tumor Cells Market Forecast: Breakup by Technology (in Million USD), 2026-2034
  • Table 3: Global: Circulating Tumor Cells Market Forecast: Breakup by Application (in Million USD), 2026-2034
  • Table 4: Global: Circulating Tumor Cells Market Forecast: Breakup by Product (in Million USD), 2026-2034
  • Table 5: Global: Circulating Tumor Cells Market Forecast: Breakup by Specimen (in Million USD), 2026-2034
  • Table 6: Global: Circulating Tumor Cells Market Forecast: Breakup by End User (in Million USD), 2026-2034
  • Table 7: Global: Circulating Tumor Cells Market Forecast: Breakup by Region (in Million USD), 2026-2034
  • Table 8: Global: Circulating Tumor Cells Market: Competitive Structure
  • Table 9: Global: Circulating Tumor Cells Market: Key Players